These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 3291282

  • 1. Use of cyclosporine for prevention of graft-versus-host disease after allogeneic bone marrow transplantation.
    Gluckman E, Devergie A, Lokiec F.
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):461-9. PubMed ID: 3291282
    [No Abstract] [Full Text] [Related]

  • 2. Cyclosporine-A as prevention for graft-versus-host disease in pediatric patients undergoing bone marrow transplants.
    Truog AW, Wozniak SP.
    Oncol Nurs Forum; 1990 Jun; 17(1):39-44. PubMed ID: 2405360
    [Abstract] [Full Text] [Related]

  • 3. Prevention of graft versus host disease following allogeneic bone marrow transplantation.
    Powles RL, Goss GD, Millar J, Maitland J, Borthwick-Clark C, Al-Jundi A.
    Tokai J Exp Clin Med; 1985 Jun; 10(2-3):133-8. PubMed ID: 3914738
    [No Abstract] [Full Text] [Related]

  • 4. A randomized prospective trial comparing cyclosporine and methotrexate given for prophylaxis of graft-versus-host disease after bone marrow transplantation.
    Biggs JC, Atkinson K, Gillett E, Downs K, Concannon A, Dodds A.
    Transplant Proc; 1986 Apr; 18(2):253-5. PubMed ID: 3515659
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A prospective randomized study of acute graft-v-host disease in 107 patients with leukemia: methotrexate/prednisone v cyclosporine A/prednisone.
    Forman SJ, Blume KG, Krance RA, Miner PJ, Metter GE, Hill LR, O'Donnell MR, Nademanee AP, Snyder DS.
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2605-7. PubMed ID: 3079090
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prospective randomized study of GVHD prevention using an anti IL2 receptor (CD25) MoAb after allogeneic bone marrow transplantation (BMT).
    Blaise D, Guyotat D, Reiffers J, Olive D, Michallet M, Bellanger C, Vernant JP, Ifrah N, Attal M, Vilmer E.
    Bone Marrow Transplant; 1991 Feb; 7 Suppl 2():150. PubMed ID: 1878689
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Combination prophylactic immunosuppression in bone marrow transplantation.
    Szer J.
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3011-2. PubMed ID: 2650415
    [No Abstract] [Full Text] [Related]

  • 16. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S, Bishop MR, Tarantolo S, Cowles MK, Reed E, Anderson JR, Vose JM, Bierman P, Armitage JO, Kessinger A.
    Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.